Articles by Sean Milmo - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Sean Milmo

Sean Milmo

Sean Milmo is a freelance writer based in Essex, United Kingdom.

Extending the Scope of Pharmacovigilance Comes at a Price
September 2, 2014

As the pharmacovigilance infrastructure becomes more entrenched in Europe, drug manufacturers are beginning to feel the burden of its high cost.

Collaboration and Innovation in European Medicine Regulation
August 1, 2014

The European Union has developed a system for evaluating, approving and monitoring the safety of medicines that has also encouraged innovation.

Regulating the Environmental Impact of Pharmaceuticals
June 2, 2014

Concern by environmentalists, regulators and manufacturers rises over the environmental impact of pharmaceuticals.

EU Steps Up Inspection Efforts
May 2, 2014

The rising incidence of medicine defects and shortages stemming from sub-standard manufacturing is forcing Europe to give higher prominence to more effective inspections procedures.

Quality by Design—Bridging the Gap between Concept and Implementation
April 2, 2014

As Europe strives to firmly incorporate quality-by-design principles, there are several key issues that still need to be addressed.

European Union Packaging Safety Features Come into Effect
March 2, 2014

Manufacturers are taking measures to comply with new package safety rules.

EMA Collaborates with HTA Assessment Networks
February 2, 2014

High technology assessments are having an impact on biosimilars development in Europe.

Early Communication with Regulators is Essential for SMEs
January 2, 2014

With SMEs gaining wider recognition as the powerhouse of research and innovation in Europe, regulatory agencies are urging companies to engage with regulators early in the drug-development process.

Regulation of Biosimilars: A Matter of Variability, Similarity, and Comparability
December 2, 2013

The European Union is strengthening its pioneering role in the regulation of biosimilars by further developing the basic rules for determining the levels of compatibility for this group of drugs. There are, however, some key issues that are not easy to resolve, as evident in a recent workshop on biosimilars organized by the European Medicines Agency (EMA).


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
FindPharma Custom Search
Click here